CO2023017378A2 - Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 - Google Patents
Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3Info
- Publication number
- CO2023017378A2 CO2023017378A2 CONC2023/0017378A CO2023017378A CO2023017378A2 CO 2023017378 A2 CO2023017378 A2 CO 2023017378A2 CO 2023017378 A CO2023017378 A CO 2023017378A CO 2023017378 A2 CO2023017378 A2 CO 2023017378A2
- Authority
- CO
- Colombia
- Prior art keywords
- binding agents
- bind
- bispecific binding
- binding
- specificity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/066141 WO2022262959A1 (en) | 2021-06-15 | 2021-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
| PCT/EP2022/066299 WO2022263508A1 (en) | 2021-06-15 | 2022-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023017378A2 true CO2023017378A2 (es) | 2024-02-05 |
Family
ID=77519090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0017378A CO2023017378A2 (es) | 2021-06-15 | 2023-12-14 | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11739145B2 (enExample) |
| EP (1) | EP4355428A1 (enExample) |
| JP (2) | JP7513854B2 (enExample) |
| KR (1) | KR20240032847A (enExample) |
| CN (1) | CN117858906A (enExample) |
| AR (1) | AR126154A1 (enExample) |
| AU (1) | AU2022292895A1 (enExample) |
| BR (1) | BR112023026566A2 (enExample) |
| CA (1) | CA3222300A1 (enExample) |
| CL (1) | CL2023003725A1 (enExample) |
| CO (1) | CO2023017378A2 (enExample) |
| IL (1) | IL308072A (enExample) |
| MX (1) | MX2023014666A (enExample) |
| TW (1) | TW202317624A (enExample) |
| WO (2) | WO2022262959A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| AU2020379735A1 (en) | 2019-11-05 | 2022-05-26 | Regeneron Pharmaceuticals, Inc. | N-terminal SCFV multispecific binding molecules |
| JP2026501506A (ja) * | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2025120866A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| AR134560A1 (es) * | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
| WO2026060339A1 (en) * | 2024-09-16 | 2026-03-19 | Merck Sharp & Dohme Llc | Human claudin 18.2 binders and uses thereof |
| WO2026101943A1 (en) * | 2024-11-06 | 2026-05-15 | Agilent Technologies, Inc. | Anti-human claudin-18.2 antibodies for in vitro diagnostics |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| JP6696982B2 (ja) * | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| BR112021002032A2 (pt) | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | construtos de anticorpos para cldn18.2 e cd3 |
| WO2021237717A1 (zh) * | 2020-05-29 | 2021-12-02 | 武汉友芝友生物制药有限公司 | 抗cldn18.2和cd3的双特异性抗体 |
-
2021
- 2021-06-15 WO PCT/EP2021/066141 patent/WO2022262959A1/en not_active Ceased
-
2022
- 2022-06-15 KR KR1020247001571A patent/KR20240032847A/ko active Pending
- 2022-06-15 MX MX2023014666A patent/MX2023014666A/es unknown
- 2022-06-15 CN CN202280042413.9A patent/CN117858906A/zh active Pending
- 2022-06-15 IL IL308072A patent/IL308072A/en unknown
- 2022-06-15 JP JP2023577405A patent/JP7513854B2/ja active Active
- 2022-06-15 TW TW111122151A patent/TW202317624A/zh unknown
- 2022-06-15 AU AU2022292895A patent/AU2022292895A1/en active Pending
- 2022-06-15 WO PCT/EP2022/066299 patent/WO2022263508A1/en not_active Ceased
- 2022-06-15 AR ARP220101578A patent/AR126154A1/es unknown
- 2022-06-15 EP EP22750661.5A patent/EP4355428A1/en active Pending
- 2022-06-15 BR BR112023026566A patent/BR112023026566A2/pt unknown
- 2022-06-15 CA CA3222300A patent/CA3222300A1/en active Pending
- 2022-12-06 US US18/062,465 patent/US11739145B2/en active Active
-
2023
- 2023-07-05 US US18/347,361 patent/US12378313B2/en active Active
- 2023-12-13 CL CL2023003725A patent/CL2023003725A1/es unknown
- 2023-12-14 CO CONC2023/0017378A patent/CO2023017378A2/es unknown
-
2024
- 2024-06-10 JP JP2024093451A patent/JP2024116283A/ja active Pending
-
2025
- 2025-07-11 US US19/267,078 patent/US20260035458A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022292895A1 (en) | 2024-01-04 |
| EP4355428A1 (en) | 2024-04-24 |
| US12378313B2 (en) | 2025-08-05 |
| JP2024116283A (ja) | 2024-08-27 |
| AR126154A1 (es) | 2023-09-13 |
| TW202317624A (zh) | 2023-05-01 |
| CA3222300A1 (en) | 2022-12-22 |
| BR112023026566A2 (pt) | 2024-03-05 |
| CN117858906A (zh) | 2024-04-09 |
| US11739145B2 (en) | 2023-08-29 |
| US20260035458A1 (en) | 2026-02-05 |
| US20240018234A1 (en) | 2024-01-18 |
| WO2022262959A1 (en) | 2022-12-22 |
| CL2023003725A1 (es) | 2024-05-17 |
| MX2023014666A (es) | 2024-01-12 |
| JP7513854B2 (ja) | 2024-07-09 |
| WO2022263508A1 (en) | 2022-12-22 |
| KR20240032847A (ko) | 2024-03-12 |
| JP2024520868A (ja) | 2024-05-24 |
| IL308072A (en) | 2023-12-01 |
| US20230137677A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003725A1 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
| MX2024015256A (es) | Proteinas trispecificas y metodos de uso | |
| BR112019022515A2 (pt) | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| MX2022008214A (es) | Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl. | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| BR112019008859A2 (pt) | anticorpos direcionados contra a morte programada 1 (pd-1) | |
| MX2022014852A (es) | Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2. | |
| MX2024009976A (es) | Composicion farmaceutica que comprende anticuerpo anti-tigit y anticuerpo bispecifico anti-pd-1/anti-vegfa y su uso. | |
| CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
| CL2023003696A1 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso | |
| CL2022001545A1 (es) | Composiciones y métodos para tratar y prevenir la influenza | |
| MX2024000678A (es) | Agentes que codifican elementos de union a cldn6 y cd3 para el tratamiento de canceres positivos para cldn6. | |
| CL2022002520A1 (es) | Anticuerpos anti-sea de muc1 | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| BR112023020574A2 (pt) | Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| MX2024014272A (es) | Anticuerpos antialergenos y usos de los mismos | |
| CO2025016192A2 (es) | Moléculas y métodos de uso de estas | |
| CO2026002111A2 (es) | Anticuerpos gucy2c y usos de estos | |
| MX2024011128A (es) | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. | |
| BR112021019337A2 (pt) | Anticorpo anti-fgf23 |